Linzagolix (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Linzagolix" in English language version.

refsWebsite

Global rank English rank

68^th place

117^th place

2^nd place

2^nd place

4^th place

4^th place

3,984^th place

2,622^nd place

low place

low place

274^th place

309^th place

5^th place

5^th place

1globenewswire.com

2,614^th place

1,549^th place

1semanticscholar.org

11^th place

8^th place

doi.org

Ezzati M, Carr BR (January 2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
Chodankar R, Allison J (2018). "New Horizons in Fibroid Management". Current Obstetrics and Gynecology Reports. 7 (2): 106–115. doi:10.1007/s13669-018-0242-6. ISSN 2161-3303.
Kotlyar AM, Pal L, Taylor HS (December 2021). "Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists". Clinical Obstetrics and Gynecology. 64 (4): 837–849. doi:10.1097/GRF.0000000000000664. PMID 34668887. S2CID 239034628.

europa.eu

ema.europa.eu

"Yselty EPAR". European Medicines Agency (EMA). 14 December 2021. Retrieved 19 August 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Yselty film-coated tablets" (PDF). Theramex Ireland Limited. European Medicines Agency.
"Yselty: Pending EC decision". European Medicines Agency. 16 December 2021. Retrieved 18 December 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

ec.europa.eu

"Yselty Product information". European Commission. EU/1/21/1606. Retrieved 24 June 2022.

globenewswire.com

"ObsEva Announces UK MHRA Marketing Authorization for Yselty (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids" (Press release). ObsEva. 28 June 2022. Retrieved 24 August 2022 – via GlobeNewswire.

nih.gov

pubmed.ncbi.nlm.nih.gov

Ezzati M, Carr BR (January 2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052.
Kotlyar AM, Pal L, Taylor HS (December 2021). "Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists". Clinical Obstetrics and Gynecology. 64 (4): 837–849. doi:10.1097/GRF.0000000000000664. PMID 34668887. S2CID 239034628.

semanticscholar.org

api.semanticscholar.org

Kotlyar AM, Pal L, Taylor HS (December 2021). "Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists". Clinical Obstetrics and Gynecology. 64 (4): 837–849. doi:10.1097/GRF.0000000000000664. PMID 34668887. S2CID 239034628.

springer.com

adisinsight.springer.com

"Linzagolix - Kissei Pharmaceutical/ObsEva". AdisInsight. Springer Nature Switzerland AG.

sps.nhs.uk

"Linzagolix". Specialist Pharmacy Service. 8 August 2022. Retrieved 24 August 2022.

tga.gov.au

https://www.tga.gov.au/resources/prescription-medicines-registrations/yselty-theramex-australia-pty-ltd

worldcat.org

search.worldcat.org

Chodankar R, Allison J (2018). "New Horizons in Fibroid Management". Current Obstetrics and Gynecology Reports. 7 (2): 106–115. doi:10.1007/s13669-018-0242-6. ISSN 2161-3303.